We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

1 hedge funds and large institutions have $18K invested in Artelo Biosciences in 2020 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more capital invested

Capital invested by funds: $15K → $18K (+$3K)

0% more funds holding

Funds holding: 1 → 1 (0)

0% less ownership

Funds ownership: 0.44% → 0.44% (-0%)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$1K

ARTL Hedge Fund Activity: Q2 2020 in Review

1 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q2 2020, worth a combined $18K — up 20% from $15K a quarter earlier.

Fund positioning in ARTL was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was UBS Group, cutting an estimated $1K.

  • 1 institutional investor held Artelo Biosciences (ARTL) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $18K of Artelo Biosciences stock for Q2 2020, up 20% quarter-over-quarter.
  • 0 funds opened new Artelo Biosciences positions in Q2 2020 and 0 closed out.
  • The largest Artelo Biosciences seller in Q2 2020 was UBS Group, an estimated $1K sold.

Based on aggregated 13F filings for Q2 2020.